Table 3. Correlation of vascular CXCR4 expression with clinicopathological patient characteristics.
| Gastric carcinoma | Patients | Vascular CXCR4 immunoreactivity | ||
| 0 | 1 | P | ||
| Total | 347 | |||
| Age, years | ||||
| ≤65, n (%) | 142 | 110 (77) | 32 (23) | p = 0.0148 |
| >65, n (%) | 151 | 97 (64) | 54 (36) | |
| Gender | ||||
| men, n (%) | 187 | 132 (71) | 55 (29) | ns (p = 1.0) |
| women, n (%) | 105 | 74 (70) | 31 (30) | |
| T category | ||||
| pT1/pT2a, n (%) | 52 | 48 (92) | 4 (8) | p = 0.0001 |
| pT2b/pT3/pT4, n (%) | 239 | 158 (66) | 81 (34) | |
| pT1/pT2, n (%) | 154 | 124 (81) | 30 (19) | p = 0.0001 |
| pT3/pT4, n (%) | 139 | 83 (60) | 56 (40) | |
| Lymph nodes | ||||
| no metastases (%) | 74 | 55 (74) | 19 (26) | ns (p = 0.463) |
| Metastases (%) | 217 | 151 (70) | 66 (30) | |
| pN0, n (%) | 74 | 55 (74) | 19 (26) | ns (p = 0.689) |
| pN1, n (%) | 105 | 75 (71) | 30 (29) | |
| pN2, n (%) | 79 | 52 (66) | 27 (34) | |
| pN3, n (%) | 33 | 24 (73) | 9 (27) | |
| M category | ||||
| pM0, n (%) | 259 | 185 (71) | 74 (29) | ns (p = 0.427) |
| pM1, n (%) | 34 | 22 (65) | 12 (35) | |
| Grade | ||||
| G1/G2, n (%) | 78 | 54 (69) | 24 (31) | ns (p = 0.773) |
| G3/G4, n (%) | 215 | 153 (71) | 62 (29) | |
| UICC | ||||
| I, n (%) | 58 | 52 (90) | 6 (10) | p = 0.0059 |
| II, n (%) | 74 | 51 (69) | 23 (31) | |
| III, n (%) | 91 | 56 (62) | 35 (38) | |
| IV, n (%) | 69 | 48 (70) | 21 (30) | |